Lund University & Eurasante are delighted to launch the 2nd edition of IDEA Summit

After its 1st launch in 2013 in Lund (Sweden), IDEA Summit comes back to Lille (France) on December 2 & 3, 2014.

Unique European event dedicated to collaboration, translational research & technology transfer in diabetes, IDEA Summit aims at:

  • Fostering academia / industries collaborations
  • Accelerating technology transfer
  • Sharing best practices for successful collaboration/research projects

IDEA Summit offers:

  • A one-to-one partnering session enabling Pharma, Biotech, TTOs & Academic Scientists to explore licensing & collaborative opportunities
  • A conference program dedicated to shed light on recent innovations and clinical achievements in the field of diabetes

PROGRAM

[accordion open=”0″] [accordion-item title=”Plenary Session: 2013-2014 Breakthroughs and innovations in the field of diabetes“]

A general overview of the last findings in the field of diabetes that have occurred during the last months. The most important events, the major breakthroughs might be summarized in order to answer the question “what has been done in diabetes for the last months?”
Different stakeholders will bear witness to their point of view.

[/accordion-item] [accordion-item title=”Track 1: What do you expect as a good level of maturity of finding? Too early stage for me guy!“]

In research collaboration between academia and industries, what is given and what is expected are different and it results that both parts are disappointed. Which type of research fields interest academia, biotech and pharma? Research institutes have to agree with biotech and pharma industries and define what is done by each actor and where does the translation start. Biotech and pharma have to clearly define what they wait from academia in term of patents and results.
In order to organize everything and have good relationships between academia and industries and to accelerate the pace of innovation in diabetes, we have to define and decide what each actor awaits the others, which place takes each stakeholder.

[/accordion-item] [accordion-item title=”Track 2: Is stratified/personalized/precision medicine one of the paradigm on which we could grind our collective efforts for research in diabetes?“]

Despite advances in pharmacology, not all patients respond favorably to drugs. Do we need to develop new drug generation? Actually there’s no innovative idea neither new target.
To cross out the lack of future innovative treatments, we need to develop an integrated approach that looks for patients and treatments and to adapt treatments to patient. In that way we don’t need only therapeutics results but also diagnostics results.

We trill try to answer the following questions:

  • What are so far the interesting of relevant subjects that have been hand out?
  • What is the value of stratified medicine in the field of diabetes? What is the reason why there are so few things?
  • What do diabetic patients, researchers and pharma expect
  • Is stratified medicine the right direction to take to improve diabetes care?
[/accordion-item] [accordion-item title=”Track 3: Do we need a European joint diabetes research agenda? Who should contribute to it? What should be the goals of this joint research agenda?“]

Many companies and research institutes are getting more and more involved in consortia of different sizes in order to work together around specific questions they all want to answer to. Their organization can be different depending on the number of partners involved and the questions addressed. We need to have a global vision of these consortia, to know where they are going and what they miss.

Some questions will be asked to lead the debate:

  • What should be the role of all stakeholders in a European joint diabetes research agenda? How can they organize together?
  • Looking at IMI and H2020 projects, can we consider all the priorities in the field of diabetes are taken into account? If not, do we need other system for European initiatives to cover diabetes innovations?
  • DO H2020 and IMI cover comprehensively diabetes research priorities?
[/accordion-item] [/accordion]

 Discover the website

[button link=”http://www.partneringone.com/registration.php?id=25644f$b7VczanGQV9wI&regtype=60844f$b7AKyXcDuljaM” size=”large” target=”_blank” icon=”” color=”blue” lightbox=”false”]Register NOW[/button]

SPONSORED BY

1299169879logo_astrazeneca

Logo Novo Nordisk

nouveau_logo_sanofi_400

Logo EGIDIDEA Summit’s 2nd edition is jointly organized with the 3rd European Genomic Institute for Diabetes (E.G.I.D.) Symposium
On December 2nd, E.G.I.D. Symposium will focus on meta-inflammation in diabetes and its complications.

EVOTEC CEO,  Dr. Werner Lanthaler will be speaking at the Plenary Session of BioFIT 2014, on December 2nd at 11am:

Accessing innovation: how to build long term partnerships?

Pharma’s interest on early stage is no longer news in the life sciences industry. In their quest to accessing knowledge, pharma and large biotech got more and more involved in early stage research, either by supporting big consortia or building collaborative research partnerships directly with academia. However, what do we know about the success of such partnerships and big consortia? Have they really worked and what were the outcomes? Where are we today in terms of long-term collaborations? Let’s hear from real experiences, what worked and what didn’t, what lessons have been learned and how have these helped in forging true partnerships.

  • Adrian CARTER, Vice President of Global Research Networking, Boehringer Ingelheim (DE)
  • Wen Hwa LEE, Strategic Alliances Manager, University of Oxford, Nuffield Department of Medicine (UK)
  • Manfred HORST, Director, Scientific Liaison France, Ge, Eastern EU Licensing & External Research EU, Merck Sharp & Dohme (FR)

Dr. Werner Lanthaler’s Biography
Dr Werner Lanthaler was appointed Chief Executive Officer of Evotec in March 2009. From March 2000 to March 2009 he was Chief Financial Officer at Intercell AG. During his tenure, Intercell developed from a venture-backed biotechnology company into a global vaccine player. Dr Lanthaler played a pivotal role in many of the company’s major corporate milestones including the product approval of Intercell’s Japanese Encephalitis Vaccine, the company’s acquisitions and strategic pharma partnerships, as well as the company’s Initial Public Offering in 2005. Previously, from 1998 to 2000 Dr Lanthaler served as Director of the Federation of Austrian Industry, and from 1995 to 1998 as Senior Management Consultant at the consulting firm McKinsey & Company.

He holds a doctorate in economics from Vienna University, earned his Master’s degrees from Harvard University, and holds a degree in Psychology.

See full program

BioFIT 2014 speakers list

Pascale REDIG, Sr Category  Manager Research & Academic Partnerships at Janssen Research & Development Procurement, JANSSEN PHARMACEUTICA will share the panel session on creative solutions to difficult problems in dealmaking.

Emerge and happen: creative solutions to difficult problems in dealmaking, on December 3rd at 11am

That things can go wrong in negotiations and partnership is not surprising. However, when you encounter these problems, sometimes creative solutions are needed in order to finally create a mutually beneficial partnership. During this interactive session, the panelists will discuss the common and no so common pitfalls in partnering and negotiations, as well as share their experience on the different stages of negotiations, the difficulties they ran into and the solutions they found.

Together with Stefan LENSKY, VP Strategic Transaction & Alliances, BOEHRINGER INGELHEIM  and Juergen WALKENHORST, Head of Life Sciences, PROVENDIS GmbH, they will discuss and answer the audience’s questions on dealmaking.

DON’T MISS the connected session giving you the key tools to best apply your strategic alliance management.

Make it work and last: how to best apply strategic alliance managemen on December 3rd at 2pm

The deal signature is just the beginning of a long road to travel for putting in place a successful partnership. The alliance management is an important piece of the puzzle and if well implemented and understood by both parties, it becomes an effective and invaluable tool in the management of the deal. Let’s discuss how to set it correctly on paper and how to identify the right key licensing terms to the deal and how to manage the partnership in an efficient and rewarding way for both parties.

Apply to share this panel with our experts

See full conference program

Check full list of  speakers

Bernd STOWASSER, Head of European Public Private Partnerships at SANOFI Germany will join BioFIT as a speaker and discuss latest issues on Big consortia: how they work and what are their outcomes.

Many companies and research institutes are getting more and more involved in consortia of different sizes in order to work together around specific questions they are all looking to find an answer to. Of course their organization can be very different depending on the number of partners involved and the questions addressed. But how can their outcomes be evaluated, knowing that what comes out is non-tangible knowledge which itself is later used in other R&D processes in order to obtain real results? Moreover, what type of guidance is necessary in order make them work and obtain successful outcomes?

Come learn more and discuss with our speakers on December 2nd at 9am.

Moderator: Hugh LAVERTY, Senior Scientific Project Manager, IMI – Innovative Medicines Initiative (BE)

Speakers:

  • Bernd STOWASSER, Head of Public Private Partnerships – External Innovation & Science Policy, Sanofi (DE)
  • Nicolas CARBONI, President, SATT Conectus Alsace (FR)
  • Jacky VONDERSCHER, President, Enyo Pharma (FR)
  • Bruno FRANCOIS, Clinical Lead COMBACTE Consortium, CHU Limoges/Inserm (FR)

Check full agenda

Check speakers